Benzinga | Aug 5, 2021 08:02AM EDT

AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation to Explore Innovative Healthcare and Medical Solutions

AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States, today announced that Announced that AnPac Bio and Roche Pharmaceuticals China ("Roche") have entered into a cooperation agreement to explore novel healthcare and medical solutions and collaboration models in early cancer screening, early diagnosis, and early treatment, through leveraging both parties' advantages and sources.

According to data from World Health Organization (WHO), there were 135 million global cancer patients in 2020, of which 32 million were from China. Global cancer patients increased 20 million annually, with 4.7 million of those in China. A large cancer patient population results in significant growth in cancer screening and companion diagnostics markets.

AnPac Bio and Roche will jointly explore personalized product lines and solutions consisting of early cancer screening, early diagnosis and early treatment. The cooperation will target general population for early cancer screening, hospital diagnosis, and precision medicine through therapy selection testing. By leveraging both parties' channels and sources, the cooperation plans to form a competitive package of products and services to enhance innovative cancer screening and follow-up tests, improve customers' affordability, and help customers to receive more innovative, affordable and high-quality healthcare and medical services.

According to the agreement, both parties plan to utilize AnPac Bio's Cancer Differentiation Analysis (CDA) cancer detection technology and Roche's FoundationOne CDx to form a full solution, under which customers assessed with a high cancer risk level using CDA tests and later diagnosed with cancer will receive CDx precision medicine test and service for therapy selection. The collaboration aims to benefit general population via reducing medical costs and saving more patients' lives.